RESUMEN

Tissue-specific progenitor cells are characterized by proliferation and differentiation, but, in contrast to embryonic stem (ES) cells, have limited capacities for self-renewal and no tumourigenic potential. These latter traits make progenitor cells an ideal source for regenerative cell therapies. In this review, we describe what is currently known about nestin, an intermediate filament first identified in neuroepithelial stem cells. During embryogenesis, nestin is expressed in migrating and proliferating cells, whereas in adult tissues, nestin is mainly restricted to areas of regeneration. We show that nestin is abundant in ES-derived progenitor cells that have the potential to develop into neuroectodermal, endodermal and mesodermal lineages. Although it remains unclear what factors regulate in vitro and in vivo expression of nestin, we conclude that nestin represents a characteristic marker of multi-lineage progenitor cells and suggest that its presence in cells may indicate multi-potentiality and regenerative potential.

Asunto(s)

Proteínas de Filamentos Intermediarios/biosíntesis , Proteínas del Tejido Nervioso/biosíntesis , Células Madre/metabolismo , Animales , Diferenciación Celular , Linaje de la Célula , Proliferación Celular , Embrión de Mamíferos/citología , Exones , Humanos , Inmunohistoquímica , Proteínas de Filamentos Intermediarios/metabolismo , Hígado/metabolismo , Ratones , Modelos Biológicos , Proteínas del Tejido Nervioso/metabolismo , Nestina , Páncreas/metabolismo , Ratas , Células Madre/citología

RESUMEN

Differences in doublet analysis have the potential to alter DNA cell-cycle measurements. The techniques for doublet determination are often used interchangeably without regard for the complexity in cell shapes and sizes of biological specimens. G(0/1) doublets were identified and quantitated using fluorescence height versus area and fluorescence width versus area pulse measurements, by enumerating the proportion of G(2) + M cells that lack cyclin B1 immunoreactivity, and modeled in the DNA histograms by software algorithms. These techniques were tested on propidium iodide-stained whole epithelial cells or nuclei from asynchronous cultures, or after exposure to chemotherapeutic agents that induced cell-cycle arrest and were extended to human breast tumor specimens having DNA diploid patterns. G(0/1) doublets were easily discernible from G(2) + M singlets in cells or nuclei that are generally homogenous and spherical in shape. Doublet discrimination based on pulse processing or cyclin B1 measurements was nonconcordant in some nonspherical cell types and in cells following cell cycle arrest. Significant differences in G(0/1) doublet estimates were observed in breast tumor specimens (n = 50), with estimates based on pulse width twice those of pulse height and nearly five times greater than computer estimates. Differences between techniques are attributed to difficulties in the separation of the boundaries between G(0/1) doublets and G(2) + M singlet populations in biologically heterogeneous specimens. To improve reproducibility and enhance standardization among laboratories performing cell cycle analysis in experimental cell systems and in human breast tumors, doublet discrimination analysis should best be accomplished by computer modeling. Shape and size heterogeneity of tumor and arrested cells using pulse-processing can lead to errors and make interlaboratory comparison difficult.

Asunto(s)

Ciclo Celular/fisiología , ADN/metabolismo , Citometría de Flujo/instrumentación , Procesamiento de Señales Asistido por Computador , Mama/citología , Neoplasias de la Mama , Carcinoma , Línea Celular , Tamaño de la Célula , Estudios de Evaluación como Asunto , Femenino , Citometría de Flujo/métodos , Humanos , Procesamiento de Señales Asistido por Computador/instrumentación

RESUMEN

Due to brain tissue heterogeneity, the molecular genetic profile of any neurotransmitter-specific neuronal subtype is unknown. The purpose of this study was to purify a population of dopamine neurons, construct a cDNA library, and generate an initial gene expression profile and a microarray representative of dopamine neuron transcripts. Ventral mesencephalic dopamine neurons were purified by fluorescent-activated cell sorting from embryonic day 13.5 transgenic mice harboring a 4.5-kb rat tyrosine hydroxylase promoter-lacZ fusion. Nine-hundred sixty dopamine neuron cDNA clones were sequenced and arrayed for use in studies of gene expression changes during methamphetamine neurotoxicity. A neurotoxic dose of methamphetamine produced a greater than twofold up-regulation of the mitochondrial cytochrome c oxidase polypeptide I transcript from adult mouse substantia nigra at 12 h posttreatment. This is the first work to describe a gene expression profile for a neuronal subtype and to identify gene expression changes during methamphetamine neurotoxicity.

Asunto(s)

Inhibidores de Captación de Dopamina/toxicidad , Dopamina/análisis , Complejo IV de Transporte de Electrones/biosíntesis , Perfilación de la Expresión Génica , Biblioteca de Genes , Metanfetamina/toxicidad , Proteínas del Tejido Nervioso/biosíntesis , Neuronas/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Ácido 3,4-Dihidroxifenilacético/análisis , Animales , ADN Complementario/genética , Complejo IV de Transporte de Electrones/genética , Inducción Enzimática , Femenino , Genes Sintéticos , Operón Lac , Masculino , Mesencéfalo/citología , Mesencéfalo/embriología , Ratones , Ratones Transgénicos , Datos de Secuencia Molecular , Proteínas del Tejido Nervioso/genética , Regiones Promotoras Genéticas , Ratas , Transcripción Genética , Tirosina 3-Monooxigenasa/genética

RESUMEN

We compared stimulus-coupling pathways involved in bovine pulmonary artery (PA) and lung microvascular endothelial cell migration evoked by sphingosine-1-phosphate (S1P), a potent bioactive lipid released from activated platelets, and by vascular endothelial growth factor (VEGF), a well-recognized angiogenic factor. S1P-induced endothelial cell migration was maximum at 1 microM (approximately 8-fold increase with PA endothelium) and surpassed the maximal response evoked by either VEGF (10 ng/ml) (approximately 2.5-fold increase) or hepatocyte growth factor (HGF) (approximately 2.5-fold increase). Migration induced by S1P, but not by VEGF, was significantly inhibited by treatment with antisense oligonucleotides directed to Edg-1 and Edg-3 (endothelial differentiation gene) S1P receptors and by G protein modification. These strategies included pretreatment with pertussis toxin, or transfection with mini-genes encoding a betagamma subunit inhibitory peptide of the beta-adrenergic receptor kinase, or an 11-amino-acid peptide that inhibits G(1alpha2) signaling. Various strategies to interrupt Rho family signaling, including C(3) exotoxin, dominant/negative Rho, or the addition of Y27632, a cell-permeable Rho kinase inhibitor, significantly attenuated S1P- but not VEGF-induced migration. Conversely, pharmacologic inhibition of either myosin light chain kinase, src family tyrosine kinases, or phosphatidylinositol-3' kinase reduced basal endothelial cell migration and abolished VEGF-induced endothelial cell migration but did not inhibit the increase in S1P-induced migration. Whereas VEGF and S1P increased both p42/p44 extracellular regulated kinase and p38 mitogen-activated protein (MAP) kinase activities, only p38 MAP kinase inhibition significantly reduced VEGF- and S1P-stimulated migration. These data confirm S1P as a potent endothelial cell chemoattractant through G(1alpha2)-coupled Edg receptors linked to Rho-associated kinase and p38 MAP kinase activation. The divergence in signaling pathways evoked by S1P and VEGF suggests complex and agonist-specific regulation of endothelial cell angiogenic responses.

Asunto(s)

Quimiotaxis/efectos de los fármacos , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/efectos de los fármacos , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/metabolismo , Linfocinas/farmacología , Lisofosfolípidos , Proteínas Proto-Oncogénicas/metabolismo , Esfingosina/farmacología , Animales , Vasos Sanguíneos/efectos de los fármacos , Bovinos , Citoesqueleto/efectos de los fármacos , Subunidad alfa de la Proteína de Unión al GTP Gi2 , Péptidos y Proteínas de Señalización Intracelular , Pulmón/irrigación sanguínea , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Cadenas Ligeras de Miosina/metabolismo , Neovascularización Fisiológica , Fosforilación , Proteínas Serina-Treonina Quinasas/metabolismo , Transducción de Señal , Esfingosina/análogos & derivados , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular , Proteínas de Unión al GTP rho/metabolismo , Quinasas Asociadas a rho

RESUMEN

Nonhuman primate model systems of autologous CD34+ cell transplant are the most effective means to assess the safety and capabilities of lentivirus vectors. Toward this end, we tested the efficiency of marking, gene expression, and transplant of bone marrow and peripheral blood CD34+ cells using a self-inactivating lentivirus vector (CS-Rh-MLV-E) bearing an internal murine leukemia virus long terminal repeat derived from a murine retrovirus adapted to replicate in rhesus macaques. In vitro cytokine stimulation was not required to achieve efficient transduction of CD34+ cells resulting in marking and gene expression of the reporter gene encoding enhanced green fluorescent protein (EGFP) following transplant of the CD34+ cells. Monkeys transplanted with mobilized peripheral blood CD34+ cells resulted in EGFP expression in 1 to 10% of multilineage peripheral blood cells, including red blood cells and platelets, stable for 15 months to date. The relative level of gene expression utilizing this vector is 2- to 10-fold greater than that utilizing a non-self-inactivating lentivirus vector bearing the cytomegalovirus immediate-early promoter. In contrast, in animals transplanted with autologous bone marrow CD34+ cells, multilineage EGFP expression was evident initially but diminished over time. We further tested our lentivirus vector system by demonstrating gene transfer of the human common gamma-chain cytokine receptor gene (gamma(c)), deficient in X-linked SCID patients and recently successfully used to treat disease. Marking was 0.42 and.001 HIV-1 vector DNA copy per 100 cells in two animals. To date, all EGFP- and gamma(c)-transplanted animals are healthy. This system may prove useful for expression of therapeutic genes in human hematopoietic cells.

Asunto(s)

Citocinas/metabolismo , Técnicas de Transferencia de Gen , Vectores Genéticos/genética , VIH-1/genética , Células Madre Hematopoyéticas/metabolismo , Macaca mulatta/metabolismo , Receptores de Superficie Celular/genética , Animales , Antígenos CD34/metabolismo , Biomarcadores , Citometría de Flujo , Expresión Génica , Factor Estimulante de Colonias de Granulocitos/farmacología , Proteínas Fluorescentes Verdes , Trasplante de Células Madre Hematopoyéticas , Humanos , Leucaféresis , Proteínas Luminiscentes , Linfocitos/metabolismo , Macaca mulatta/genética , Reacción en Cadena de la Polimerasa , Receptores de Superficie Celular/química , Receptores de Superficie Celular/metabolismo , Factor de Células Madre/farmacología , Factores de Tiempo , Transducción Genética

RESUMEN

The fibronectin fragment CH-296 improved gene transfer to cytokine-mobilized nonhuman primate CD34+ cells irrespective of tropism to the MoMLV, GaLV, and VSV-G envelope proteins using murine stem cell virus (MSCV) and human immunodeficiency virus-1 (HIV-1)-based retrovirus vectors. For the HIV-1 lentivirus vector, CH-296 enhanced gene transfer in the absence of added hematopoietic growth factors necessary for ex vivo stem cell expansion. In the presence of CH-296, apoptosis of CD34+ cells was inhibited, and in mobilized peripheral blood CD34+ cells, cell division was stimulated as measured by cell history/tracking experiments.

Asunto(s)

Fibronectinas/genética , Gammaretrovirus/genética , Técnicas de Transferencia de Gen , Vectores Genéticos , VIH-1/genética , Células Madre Hematopoyéticas/metabolismo , Animales , Antígenos CD34 , Apoptosis , Línea Celular , Fibronectinas/metabolismo , Terapia Genética , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Macaca mulatta , Virus de la Leucemia Murina de Moloney/genética , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/metabolismo , Transducción Genética , Tropismo , Proteínas del Envoltorio Viral/genética , Replicación Viral

RESUMEN

A unique feature of SW480 and SW620 colon carcinoma cell lines is that they are derived from primary and secondary tumours resected from a single patient. As such, they may represent a valuable resource for examining genetic changes late in colon cancer progression. In order to verify this, both cell lines have been characterized to determine whether phenotypic differences have been retained despite long-term cell culture in vitro. The primary tumour-derived SW480 cells have an epithelioid morphology in vitro, while metastasis-derived SW620 cells have a fibroblast-like appearance. Xenografts of SW480 cells form gland-like structures in vivo, while SW620 xenografts form solid sheets of tumour cells. SW620 cells have a higher BrdU labelling index than SW480 cells, and are more highly tumourigenic and metastatic. Furthermore, SW620 cells show less susceptibility to apoptosis induction by TNFalpha and anti-Fas monoclonal. Findings from these investigations therefore indicate that SW480 and SW620 cell lines do show appropriate phenotypic differences and represent an interesting model for studying the genetic events in the late stages of colon cancer progression.

Asunto(s)

Neoplasias del Colon/patología , Modelos Biológicos , Animales , Apoptosis , Adhesión Celular , Ciclo Celular , Movimiento Celular , Progresión de la Enfermedad , Femenino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Metástasis de la Neoplasia , Trasplante de Neoplasias , Trasplante Heterólogo , Células Tumorales Cultivadas

RESUMEN

We have used a murine retrovirus vector containing an enhanced green fluorescent protein complimentary DNA (EGFP cDNA) to dynamically follow vector-expressing cells in the peripheral blood (PB) of transplanted rhesus macaques. Cytokine mobilized CD34(+) cells were transduced with an amphotropic vector that expressed EGFP and a dihydrofolate reductase cDNA under control of the murine stem cell virus promoter. The transduction protocol used the CH-296 recombinant human fibronectin fragment and relatively high concentrations of the flt-3 ligand and stem cell factor. Following transplantation of the transduced cells, up to 55% EGFP-expressing granulocytes were obtained in the peripheral circulation during the early posttransplant period. This level of myeloid marking, however, decreased to 0.1% or lower within 2 weeks. In contrast, EGFP expression in PB lymphocytes rose from 2%-5% shortly following transplantation to 10% or greater by week 5. After 10 weeks, the level of expression in PB lymphocytes continued to remain at 3%-5% as measured by both flow cytometry and Southern blot analysis, and EGFP expression was observed in CD4(+), CD8(+), CD20(+), and CD16/56(+) lymphocyte subsets. EGFP expression was only transiently detected in red blood cells and platelets soon after transplantation. Such sustained levels of lymphocyte marking may be therapeutic in a number of human gene therapy applications that require targeting of the lymphoid compartment. The transient appearance of EGFP(+) myeloid cells suggests that transduction of a lineage-restricted myeloid progenitor capable of short-term engraftment was obtained with this protocol. (Blood. 2000;95:445-452)

Asunto(s)

Citocinas/farmacología , Granulocitos/citología , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/citología , Proteínas Luminiscentes/genética , Tetrahidrofolato Deshidrogenasa/genética , Transfección/métodos , Animales , ADN Complementario/administración & dosificación , Fibronectinas/farmacología , Proteínas Fluorescentes Verdes , Movilización de Célula Madre Hematopoyética , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/fisiología , Humanos , Proteínas Luminiscentes/biosíntesis , Subgrupos Linfocitarios/inmunología , Linfocitos/citología , Linfocitos/inmunología , Macaca mulatta , Fragmentos de Péptidos/farmacología , Regiones Promotoras Genéticas , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes/farmacología , Tetrahidrofolato Deshidrogenasa/biosíntesis

RESUMEN

Recently, gene delivery vectors based on human immunodeficiency virus (HIV) have been developed as an alternative mode of gene delivery. These vectors have a number of advantages, particularly in regard to the ability to infect cells which are not actively dividing. However, the use of vectors based on human immunodeficiency virus raises a number of issues, not the least of which is safety; therefore, further characterization of marking and gene expression in different hematopoietic lineages in primate animal model systems is desirable. We use two animal model systems for gene therapy to test the efficiency of transduction and marking, as well as the safety of these vectors. The first utilizes the rhesus animal model for cytokine-mobilized autologous peripheral blood CD34(+) cell transplantation. The second uses the SCID-human (SCID-hu) thymus/liver chimeric graft animal model useful specifically for human T-lymphoid progenitor cell reconstitution. In the rhesus macaques, detectable levels of vector were observed in granulocytes, lymphocytes, monocytes, and, in one animal with the highest levels of marking, erythrocytes and platelets. In transplanted SCID-hu mice, we directly compared marking and gene expression of the lentivirus vector and a murine leukemia virus-derived vector in thymocytes. Marking was observed at comparable levels, but the lentivirus vector bearing an internal cytomegalovirus promoter expressed less efficiently than did the murine retroviral vector expressed from its own long terminal repeats. In assays for infectious HIV type 1 (HIV-1), no replication-competent HIV-1 was detected in either animal model system. Thus, these results indicate that while lentivirus vectors have no apparent deleterious effects and may have advantages over murine retroviral vectors, further study of the requirements for optimal use are warranted.

Asunto(s)

Antígenos CD34/análisis , Expresión Génica , Vectores Genéticos , VIH-1/genética , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/metabolismo , Linfocitos T/metabolismo , Animales , Citomegalovirus/genética , Proteínas Fluorescentes Verdes , Células Madre Hematopoyéticas/virología , Humanos , Virus de la Leucemia Murina/genética , Leucopoyesis , Trasplante de Hígado/inmunología , Proteínas Luminiscentes/biosíntesis , Proteínas Luminiscentes/genética , Activación de Linfocitos , Macaca mulatta , Ratones , Ratones SCID , Regiones Promotoras Genéticas , Linfocitos T/inmunología , Linfocitos T/virología , Timo/inmunología , Timo/trasplante , Transducción Genética , Replicación Viral

RESUMEN

The transduction efficiencies of immunoselected rhesus macaque (Macaca mulatta) CD34+ cells and colony-forming progenitor cells based on polymerase chain reaction (PCR) analysis were comparable for an amphotropic Moloney murine leukemia virus (MLV) retroviral vector and a retroviral vector derived from the gibbon ape leukemia virus (GaLV) packaging cell line, PG13. On performing autologous transplantation studies using immunoselected CD34+ cells transduced with the GaLV envelope (env) retroviral vector, less than 1% of peripheral blood (PB) contained provirus. This was true whether bone marrow (BM) or cytokine-mobilized PB immunoselected CD34+ cells were reinfused. This level of marking was evident in two animals whose platelet counts never fell below 50,000/microliter and whose leukocyte counts had recovered by days 8 and 10 after having received 1.7 x 10(7) or greater of cytokine-mobilized CD34+ PB cells/kg. Reverse transcriptase(RT)-PCR analysis of CD34+ subsets for both the GaLV and amphotropic receptor were performed. The expression of the GaLV receptor was determined to be restricted to CD34+ Thy-1+ cells, and both CD34+ CD38+ and CD34+ CD38dim cells, while the amphotropic receptor was present on all CD34+ cell subsets examined. Our findings suggest that, in rhesus macaques, PG13-derived retroviral vectors may only be able to transduce a subset of CD34+ cells as only CD34+ Thy-1+ cells express the GaLV receptor.

Asunto(s)

Antígenos CD34 , Antígenos CD , Vectores Genéticos/genética , Trasplante de Células Madre Hematopoyéticas , Virus de la Leucemia del Gibón/genética , Virus de la Leucemia Murina de Moloney/genética , Transfección/métodos , ADP-Ribosil Ciclasa , ADP-Ribosil Ciclasa 1 , Animales , Antígenos de Diferenciación , Expresión Génica , Células Madre Hematopoyéticas/inmunología , Macaca mulatta , NAD+ Nucleosidasa , Antígenos Thy-1

RESUMEN

First-generation adenovirus (Ad) vectors that had been rendered replication defective by removal of the E1 region of the viral genome (DeltaE1) or lacking the Ad E3 region in addition to E1 sequences (DeltaE1DeltaE3) induced G2 cell cycle arrest and inhibited traverse across G1/S in primary and immortalized human bronchial epithelial cells. Cell cycle arrest was independent of the cDNA contained in the expression cassette and was associated with the inappropriate expression and increase in cyclin A, cyclin B1, cyclin D, and cyclin-dependent kinase p34(cdc2) protein levels. In some instances, infection with DeltaE1 or DeltaE1 DeltaE3 Ad vectors produced aneuploid DNA histogram patterns and induced polyploidization as a result of successive rounds of cell division without mitosis. Cell cycle arrest was absent in cells infected with a second-generation DeltaE1Ad vector in which all of the early region E4 except the sixth open reading frame was also deleted. Consequently, E4 viral gene products present in DeltaE1 or DeltaE1 DeltaE3 Ad vectors induce G2 growth arrest, which may pose new and unintended consequences for human gene transfer and gene therapy.

Asunto(s)

Adenovirus Humanos/genética , Adenovirus Humanos/patogenicidad , Ciclinas/genética , Técnicas de Transferencia de Gen , Vectores Genéticos , Aneuploidia , Ciclo Celular , Línea Celular , Ciclinas/metabolismo , Virus Defectuosos/genética , Virus Defectuosos/patogenicidad , Fase G2 , Eliminación de Gen , Expresión Génica , Terapia Genética , Genoma Viral , Humanos , Recombinación Genética , Fase S , Replicación Viral/genética

Asunto(s)

Técnicas de Transferencia de Gen , Células Madre Hematopoyéticas , Proteínas Luminiscentes , Animales , Biomarcadores , Separación Celular , Terapia Genética/métodos , Proteínas Fluorescentes Verdes , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/citología , Humanos , Macaca mulatta , Proteínas de la Membrana

RESUMEN

We constructed an adenoviral vector containing human p16 cDNA in order to evaluate the cytotoxic effects of exogenous p16 expression on cancer cell proliferation and to explore the potential use of p16 in cancer gene therapy. Following infection of human breast (MCF-7, MDA-MB-231, and BT549), osteosarcoma (U-2 OS and Saos-2), cervical (C33a), and lung cancer (H358) cell lines with the recombinant adenovirus Adp16, high levels of p16 expression were observed in all cell lines. Cancer cell lines which were mutant or null for p16 but wild-type for the retinoblastoma gene product (pRb) (MCF-7, MDA-MB-231, BT549 and U-2 OS) were 7-22-fold more sensitive to the cytotoxic effects of Adp16 than to a control virus. In contrast, cancer cell lines which were wild-type for p16 but mutant or null for pRb (Saos-2, C33a and H358) were

Asunto(s)

Adenoviridae/genética , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Terapia Genética , Neoplasias/terapia , Proteínas Proto-Oncogénicas , Proteína de Retinoblastoma/análisis , Bromodesoxiuridina/metabolismo , Ciclo Celular , Quinasa 4 Dependiente de la Ciclina , Inhibidor p16 de la Quinasa Dependiente de Ciclina/análisis , Quinasas Ciclina-Dependientes/metabolismo , Humanos , Fosforilación , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/análisis

RESUMEN

The cytotoxicity of a recombinant adenovirus expressing the wild type tumor suppressor gene p53 (AdWTp53) was studied in two human breast cancer MCF-7 sublines selected for resistance to adriamycin (MCF-Adr) and mitoxantrone (MCF-Mito). Although the levels of wild type p53 protein following infection with AdWTp53 are comparable in all cell lines, the two drug-resistant MCF-7 sublines were 300- and 18-fold more sensitive to killing by AdWTp53 compared with the drug-sensitive parental MCF-7 cell lines. In each cell line, AdWTp53 infection led to cell cycle arrest, and reduction of Cdk2 and cyclin B1-Cdc2 activity. Nucleosomal DNA fragmentation analysis (as a function of apoptosis) following AdWTp53 infection revealed that, while the parental MCF-7 cells failed to undergo apoptosis, both drug-resistant cell lines showed distinct DNA laddering. In MCF-Adr cells, a combination treatment of AdWTp53 and adriamycin was much more toxic than either of the reagents used individually. Finally, exposure of a mixed population of MCF-Adr and CD34+ cells to AdWTp53 selectively prevented MCF-Adr cell colony formation, while there was no inhibition of CFU-GM colony formation from CD34+ cells. These findings suggest that some drug-resistant human breast cancers may be effectively treated with adenovirus expressing wild type p53.

Asunto(s)

Apoptosis , Neoplasias de la Mama/patología , Genes p53 , Terapia Genética/métodos , Adenoviridae , Purgación de la Médula Ósea , Neoplasias de la Mama/terapia , Ciclo Celular/efectos de los fármacos , Ciclo Celular/fisiología , Supervivencia Celular/efectos de los fármacos , Ensayo de Unidades Formadoras de Colonias , Fragmentación del ADN , Doxorrubicina/toxicidad , Resistencia a Múltiples Medicamentos , Resistencia a Antineoplásicos , Femenino , Células Madre Hematopoyéticas/citología , Humanos , Mitoxantrona/toxicidad , Transfección , Proteína p53 Supresora de Tumor/biosíntesis

RESUMEN

Carboxyamidotriazole (CAI) is a calcium influx inhibitor that has both antiproliferative and antimetastatic activities. Pretreatment of human T-cells with micromolar concentrations of CAI causes a near complete inhibition of calcium-regulated mitogen-induced transcription from the human immunodeficiency virus (HIV) long terminal repeat (LTR). This inhibition is selective since other mitogen-activated gene regulatory elements, such as the 12-O-tetradecanoylphorbol-13-acetate response element, are not influenced by the drug. HIV LTR transcription inhibition is maximal at 1.0 microM CAI, requires a pretreatment interval of at least 8 h for optimum inhibition, and shows no acute interference with the growth properties of the cells. Moreover, the inhibition is rapidly reversible upon removal of the drug from the medium. Studies to identify enhancer elements within the HIV LTR that are functionally sensitive to low-dose long-term pretreatment with CAI indicate that the NF-kappaB-binding sites are among the major targets of drug action. In vitro DNA binding studies with nuclear extracts prepared from mitogen-induced T-cells stimulated in the presence of CAI indicate that the drug differentially influences the calcium-regulated downstream signal transduction pathways necessary for specific NF-kappaB DNA binding activity at the two kappaB sites within the HIV LTR. Studies with ionomycin and thapsigargin show that repression is specific for selected modes of inducible calcium entry and indicate that, in T-cells, a major mechanism of CAI action is to modulate calcium influx at a level that is proximal to the regulated release of calcium from intracellular stores. Measurement of calcium influx in CAI-treated cells reveals a dramatic and reversible inhibition of mitogen-induced calcium influx. These results indicate that CAI can be an important and effective pharmacological tool for analysis of the calcium-dependent modulation of HIV LTR transcription.

Asunto(s)

Fármacos Anti-VIH/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Calcio/metabolismo , Duplicado del Terminal Largo de VIH/genética , VIH-1/efectos de los fármacos , Mitógenos/farmacología , Activación Transcripcional/efectos de los fármacos , Triazoles/farmacología , Sondas de ADN/metabolismo , ADN Viral/metabolismo , Relación Dosis-Respuesta a Droga , Genes Reguladores , VIH-1/genética , Humanos , Células Jurkat , FN-kappa B/genética , Transfección

RESUMEN

In order to elucidate the biochemical mechanisms by which the universal cyclin kinase inhibitor p27Kip1 regulates cell cycle progression in human breast cancer cells, a recombinant adenovirus expressing human p27 was constructed (Adp27). Upon infection of human breast cancer cells MDA-MB-231 and MCF-7 with Adp27, a high level of p27 expression was observed, and this resulted in a marked decrease in the proportion of cells in S-phase. In multiple cell lines, comparison of the cytotoxicity of Adp27 with another adenovirus vector expressing the related universal cyclin kinase inhibitor WAF1/Cip1 (AdWAF1), showed Adp27 to be markedly more (up to 56-fold) toxic than AdWAF1. DNA histograms showed Adp27 to cause a G1/S arrest at lower viral doses than AdWAF1. Analysis of cyclin dependent kinase activity following Adp27 infections showed decreased Cdk2 and cyclin B1-Cdc2 activity at lower viral doses when compared with AdWAF1. Adp27 is therefore potentially useful for studies of growth regulation and for gene therapy when growth inhibition is desired.

Asunto(s)

Adenoviridae/genética , Neoplasias de la Mama/patología , Proteínas de Ciclo Celular , Ciclo Celular/genética , Quinasas Ciclina-Dependientes/metabolismo , Proteínas Asociadas a Microtúbulos/genética , Proteínas Supresoras de Tumor , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/genética , Inhibidor p27 de las Quinasas Dependientes de la Ciclina , Humanos , Células Tumorales Cultivadas

RESUMEN

Agents such as thapsigargin and endothelin elevate intracellular calcium levels by a combination of calcium release from intracellular stores and calcium influx across the plasma membrane; however, the relative contribution of influx vs. release in modulating calcium-dependent gene expression is not as well understood in nonexcitable cells as in excitable cells. In this report we have been able to separate thapsigargin-induced elevation of intracellular calcium into release and influx components, using carboxyamido-triazole (CAI), a known inhibitor of calcium influx with antiproliferative activity against a number of human carcinomas, to selectively inhibit influx without affecting release. The results of these experiments indicate that the ability of thapsigargin to induce calcium-dependent gene expression in nonexcitable cells is dependent on the induction of calcium influx, presumably through store-operated calcium channels. CAI treatment specifically inhibited thapsigargin- or endothelin-stimulated expression from the c-fos promoter in Rat-1 cells and in epithelial cell lines derived from ovary and breast. Use of the VL30 model system confirmed the ability of CAI to inhibit calcium-dependent gene expression and further demonstrated that the ability of elevated calcium to synergize with other signaling pathways required close temporal coupling. In addition to inhibiting endothelin-induced calcium influx, CAI treatment also resulted in a partial inhibition of IP3 production and calcium release. CAI treatment also blocked the increase in ERK1 kinase activity observed in response to either endothelin or thapsigargin, suggesting a role for calcium influx in the activation of mitogen-activated protein kinase pathways.

Asunto(s)

Bloqueadores de los Canales de Calcio/farmacología , Calcio/fisiología , Endotelina-1/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Genes fos/efectos de los fármacos , Tapsigargina/farmacología , Triazoles/farmacología , Animales , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Línea Celular , Cloranfenicol O-Acetiltransferasa/genética , Cloranfenicol O-Acetiltransferasa/metabolismo , Endotelina-1/antagonistas & inhibidores , Activación Enzimática/efectos de los fármacos , Genes Reporteros/efectos de los fármacos , Genes Reporteros/genética , Genes fos/genética , Imidazoles/farmacología , Ratas , Tapsigargina/antagonistas & inhibidores

RESUMEN

The calcium influx inhibitor and cytostatic agent, 5-amino-1-1(4'-chlorobenzoyl-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide (CAI), is in phase I clinical trial for patients with refractory cancer. Additional chromatography peaks were observed during HPLC analysis of patient samples. Identification and characterization of physiological metabolites were undertaken using HPLC techniques developed for their purification from blood, pleural fluid, and urine samples. A hydrophobic metabolite, M1, was purified and functionally characterized. Structural analysis of the purified compound indicated that it is a 3,5-dichloro-4(p-chlorobenzoyl)-benzoic acid. Quantitative analysis of M1 concentration during CAI administration indicated that the rise in M1 concentration lagged behind that of CAI and persisted after CAI was no longer detectable. No clear relationship between CAI or M1 and either toxicity or efficacy was observed. Chromatography of patient blood and urine samples under conditions favoring hydrophilic metabolite detection suggested the presence of a glucuronide compound; this was also indicated by sample treatment with beta-glucuronidase. Attempts at purification did not yield a compound stable for structural analysis. The benzophenone metabolite, M1, was nonfunctional in assays of calcium influx inhibition or proliferation. No pharmacodynamic associations were observed for these metabolites, nor was there pharmacological activity of the M1 as an individual agent. These data suggest that CAI is processed into triazole and benzophenone moieties by phase I metabolism, and these metabolites or the parent compound may be conjugated for excretion by glucuronidation.

Asunto(s)

Antineoplásicos/farmacocinética , Triazoles/química , Triazoles/farmacocinética , Ácido Araquidónico/metabolismo , Líquido Ascítico/metabolismo , Benzoatos/química , Benzoatos/metabolismo , Benzoatos/farmacología , Calcio/metabolismo , División Celular/efectos de los fármacos , Línea Celular , Cromatografía Líquida de Alta Presión , Exudados y Transudados/metabolismo , Glucuronatos/química , Glucuronatos/aislamiento & purificación , Glucuronatos/metabolismo , Glucuronidasa/química , Humanos , Pulmón/metabolismo , Triazoles/sangre , Células Tumorales Cultivadas/efectos de los fármacos

RESUMEN

Specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), the most common autosomal recessive fatal genetic disease of Caucasians, result in the loss of epithelial cell adenosine 3',5'-cyclic-monophosphate (cAMP)-stimulated Cl- conductance. We show that the influx of a fluorescent dye, dihydrorhodamine 6G (dR6G), is increased in cells expressing human CFTR after retrovirus- and adenovirus-mediated gene transfer. dR6G influx is stimulated by cAMP and is inhibited by antagonists of cAMP action. Dye uptake is ATP-dependent and inhibited by Cl- removal or the addition of 10 mM SCN-. Increased staining is associated with functional activation of CFTR Cl- permeability. dR6G staining enables both the fluorescent assessment of CFTR function and the identification of successfully corrected cells after gene therapy.

Asunto(s)

Cloruros/metabolismo , AMP Cíclico/fisiología , Regulador de Conductancia de Transmembrana de Fibrosis Quística/biosíntesis , Colorantes Fluorescentes/farmacocinética , Expresión Génica , Células 3T3 , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Adenoviridae , Animales , Transporte Biológico , Bronquios , Línea Celular , AMP Cíclico/análogos & derivados , AMP Cíclico/farmacología , Fibrosis Quística/genética , Fibrosis Quística/metabolismo , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Endocitosis , Epitelio , Vectores Genéticos , Humanos , Cinética , Ratones , Microscopía Fluorescente , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/metabolismo , Retroviridae , Rodaminas/farmacocinética , Coloración y Etiquetado , Tionucleótidos/farmacología , Transfección

Asunto(s)

Neoplasias/terapia , Transducción de Señal , Animales , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Calcio/fisiología , Bloqueadores de los Canales de Calcio/farmacología , Bloqueadores de los Canales de Calcio/uso terapéutico , Ensayos Clínicos como Asunto , Proteínas de Unión al GTP/antagonistas & inhibidores , Proteínas de Unión al GTP/fisiología , Sustancias de Crecimiento/fisiología , Humanos , Activación del Canal Iónico/efectos de los fármacos , Canales Iónicos/efectos de los fármacos , Ratones , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas de Neoplasias/fisiología , Neoplasias/fisiopatología , Oncogenes , Fosfatidilinositol 3-Quinasas , Fosfatidilinositol Diacilglicerol-Liasa , Hidrolasas Diéster Fosfóricas/fisiología , Fosfotransferasas (Aceptor de Grupo Alcohol)/antagonistas & inhibidores , Fosfotransferasas (Aceptor de Grupo Alcohol)/fisiología , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/fisiología , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/fisiología , Proteínas Proto-Oncogénicas p21(ras)/antagonistas & inhibidores , Proteínas Proto-Oncogénicas p21(ras)/fisiología , Proteínas Tirosina Quinasas Receptoras/antagonistas & inhibidores , Proteínas Tirosina Quinasas Receptoras/fisiología , Transducción de Señal/efectos de los fármacos , Triazoles/farmacología , Triazoles/uso terapéutico